Site-directed mutagenesis revealed distinct receptor residue networks that control how dual and triple agonist peptides activate GLP-1 and glucagon receptors, providing a blueprint for designing improved multi-target metabolic drugs.
Each agonist has a unique receptor activation fingerprintThree dual agonists and one triple agonist each activated GLP-1 and glucagon receptors through distinct residue networks with different cAMP and ERK1/2 signaling patterns
What the researchers found
Using site-directed mutagenesis, researchers identified specific amino acid residues in the GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) that are critical for activation by multi-target peptide agonists. Three dual agonists (peptide 15, MEDI0382, and SAR425899) and one triple agonist (peptide 20) were compared to the natural hormones GLP-1 and glucagon across two signaling pathways — cAMP accumulation and ERK1/2 phosphorylation.
The results revealed distinct residue networks that control how each multi-target agonist activates these receptors, and showed that the signaling patterns differ significantly between the agonists. This means each dual/triple agonist has its own unique 'fingerprint' of receptor activation, which could be exploited to design drugs with optimized therapeutic profiles and reduced side effects.
Why it matters
Multi-target peptide agonists like tirzepatide (dual GIP/GLP-1) and emerging triple agonists (GLP-1/GIP/glucagon) represent the next wave of metabolic disease drugs. But designing a single peptide that hits multiple receptors with the right balance of activity is extraordinarily challenging. This study provides a molecular roadmap — identifying which receptor residues matter most for each agonist — that could enable rational design of next-generation multi-target peptides with optimized efficacy and safety profiles.
The numbers in context
3 dual agonists tested (peptide 15, MEDI0382, SAR425899) · 1 triple agonist (peptide 20) · 2 signaling pathways (cAMP, pERK1/2) · 2 receptors (GLP-1R, GCGR) · distinct residue networks identified for each agonist
How the study worked
Structure-based site-directed mutagenesis was used to create receptor variants with specific amino acid changes in GLP-1R and GCGR. Pharmacological assays measured agonist-induced cAMP accumulation and ERK1/2 phosphorylation for three dual agonists and one triple agonist compared to native GLP-1 and glucagon. The results mapped residue networks critical for multi-target agonist signaling at each receptor.
Who was studied
In vitro receptor mutagenesis and pharmacological assays
What this study cannot tell us
This is entirely an in vitro study using mutant receptors in cell systems, which may not capture the full complexity of receptor signaling in living organisms. Only two signaling pathways were measured; other downstream effects (β-arrestin recruitment, receptor internalization) were not assessed. The clinical relevance of the specific signaling differences identified requires validation in animal models. The study examines receptors in isolation rather than in the context of receptor dimerization or interaction with accessory proteins.
How to read the evidence
This study is graded as preliminary because it is entirely in vitro, examining receptor-level interactions without in vivo validation. However, the mechanistic insights are valuable for the rational design of multi-target peptide drugs that are in active clinical development.
When this study was published
Published in 2023, this study is directly relevant to the current wave of multi-target incretin agonist development, including clinical candidates beyond tirzepatide.
The bigger picture
Multi-target peptide agonists are reshaping metabolic medicine — tirzepatide's success proved the concept, and triple agonists targeting GLP-1, GIP, and glucagon receptors are in clinical trials. But designing these peptides has been largely empirical. This study provides the first detailed molecular map of how multi-target agonists interact with their receptors, enabling a shift from trial-and-error to rational drug design. Understanding biased signaling (where different agonists produce different signal patterns at the same receptor) could lead to drugs that maximize weight loss and glucose control while minimizing nausea and other side effects.
Questions still open
- Can the distinct signaling profiles of different dual/triple agonists predict their clinical side effect profiles?
- Would incorporating biased signaling optimization into peptide drug design produce therapeutics with better efficacy-to-side-effect ratios?
- How do the receptor residue networks identified in this study change when GIP receptor interactions are also included for triple agonists?
Common questions
What are dual and triple agonists?
Why does it matter that different agonists activate receptors differently?
Read the original research
Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists.
Acta pharmacologica Sinica, 44(2), 421-433
Citation
Darbalaei, Sanaz; Chang, Ru-Lue; Zhou, Qing-Tong; Chen, Yan; Dai, An-Tao; Wang, Ming-Wei; Yang, De-Hua. (2023). Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists.. Acta pharmacologica Sinica, 44(2), 421-433. https://doi.org/10.1038/s41401-022-00962-y